cediranib + etoposide + cisplatin

Cediranib + etoposide + cisplatin is a **combination drug regimen** investigated primarily as first-line therapy for **extensive-stage small-cell lung cancer (SCLC)** and metastatic neuroendocrine non-small-cell lung cancer (NEC)[1][4][7]. **Cediranib** is an oral, potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, targeting angiogenesis—critical for tumor growth and metastasis. **Etoposide** is a topoisomerase II inhibitor, disrupting DNA synthesis, while **cisplatin** is a platinum-based DNA crosslinking agent, together exerting broad cytotoxic and anti-proliferative effects[1][4]. The regimen has shown promising clinical activity and manageable toxicity as first-line therapy for SCLC and NEC[1][4][7]. Cediranib is developed by AstraZeneca and has been studied under code name AZD2171/brand name Recentin[2][6][8].

Other names

cediranib maleate + etoposide + cisplatin